Karen Drexler has served as a ResMed director since November 2017, and is a member of the compensation and nominating and governance committees.
Ms. Drexler is a serial entrepreneur with expertise in the fields of digital health, medical devices, and diagnostics. Currently, she serves on the boards of Outset Medical (NASDAQ: OM), a medtech company innovating dialysis treatment; Tivic Health (NASDAQ: TIVC), a bioelectric medicine company focused on relief of congestion and sinus pain; VIDA Diagnostics, the leading company in Al-powered lung intelligence solutions; EBR Systems, Inc. (ASX: EBR), maker of a wireless cardiac pacing system for people with heart failure; and Huma.ai, a company using natural language queries to extract unique insights from complex medical data.
From 2016 to 2020, Ms. Drexler was the CEO and a board member of Sandstone Diagnostics, Inc., a private company developing instruments and consumables for point-of-care medical testing. From 2011 to 2017, she served as board chair of Hygieia, Inc., a digital insulin therapy company, and remains involved as an advisor to the CEO. She also acts as a senior strategic advisor for several other early-stage companies, and spent 11 years on the board of the Keller Center for Innovation in Engineering Education at Princeton University.
Ms. Drexler is an active mentor and advisor with Astia, a global nonprofit that supports high-potential female founders. She is a founding member of Astia Angels, a network of individual investors who fund such founders, and a lead mentor with StartX, the Stanford University incubator. She is also on the Life Science and Women’s Health Councils for Springboard, an accelerator for women-led technology-oriented companies. Through her work with Astia, Springboard, and StartX, she interacts with many promising young medtech companies.
Ms. Drexler was founder, president, and CEO of Amira Medical Inc., a private company focused on minimally invasive glucose monitoring technology, from 1996 until it was sold to Roche Holding AG in 2001. Before Amira Medical, she held management roles at LifeScan and played a key role in its sale to Johnson & Johnson (NYSE: JNJ).
Ms. Drexler graduated magna cum laude with a B.S.E. in chemical engineering from Princeton University, and earned an M.B.A. with honors from the Stanford University Graduate School of Business.
What is Karen Drexler's net worth?
The estimated net worth of Karen Drexler is at least $1.74 million as of February 2nd, 2023. Ms. Drexler owns 7,987 shares of ResMed stock worth more than $1,741,645 as of April 28th. This net worth estimate does not reflect any other assets that Ms. Drexler may own. Learn More about Karen Drexler's net worth.
How do I contact Karen Drexler?
Has Karen Drexler been buying or selling shares of ResMed?
Karen Drexler has not been actively trading shares of ResMed within the last three months. Most recently, Karen Drexler sold 594 shares of the business's stock in a transaction on Thursday, February 2nd. The shares were sold at an average price of $226.58, for a transaction totalling $134,588.52. Following the completion of the sale, the director now directly owns 7,987 shares of the company's stock, valued at $1,809,694.46. Learn More on Karen Drexler's trading history.
Who are ResMed's active insiders?
ResMed's insider roster includes Carol Burt (Director), Robert Douglas (COO), Karen Drexler (Director), Michael Farrell (CEO), Peter Farrell (Director), Kaushik Ghoshal (Insider), James Hollingshead (Insider), Justin Leong (Insider), David Pendarvis (Insider), Michael Rider (General Counsel), Brett Sandercock (CFO), Rajwant Sodhi (Insider), and Ronald Taylor (Director). Learn More on ResMed's active insiders.
Are insiders buying or selling shares of ResMed?
In the last twelve months, insiders at the medical equipment provider sold shares 25 times. They sold a total of 67,970 shares worth more than $12,960,582.02. The most recent insider tranaction occured on March, 4th when General Counsel Michael J Rider sold 81 shares worth more than $14,580.00. Insiders at ResMed own 1.2% of the company.
Learn More about insider trades at ResMed. Information on this page was last updated on 3/4/2024.
